Highest-materiality recent filing
Harvard Apparatus Regenerative Technology borrows $400K from CEO via two bridge notes at 8% interest
On May 8 and July 16, 2026, company issued bridge notes totaling $400,000 to CEO Junli He.
Harvard Apparatus Regenerative Technology amends 8-K; discloses $300K bridge note from CEO
Amendment corrects prior 8-K: loan from CEO Junli He was a new agreement, not a termination.
Annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved
Junli (Jerry) He elected with 12.8M votes for, 0.86M withheld; James Shmerling with 10.7M for, 2.9M withheld; Mao Zhang with 12.8M for, 0.86M withheld.
Harvard Apparatus Regenerative Technology treats first patient in Phase 1 esophageal implant trial
First patient treated with Cellspan Esophageal Implant (CEI) in Phase 1 clinical trial at Mayo Clinic.
Harvard Apparatus receives $300K bridge loan from CEO Junli He at 8% interest
Loan of $300,000 from Chairman/CEO Junli He; annual 8% fixed interest rate.
Sold 411,765 shares of common stock at $1.70 per share for aggregate proceeds of approximately $0.7 million.
Harvard Apparatus raises $2.0M via private placement of 1.25M shares at $1.60/share
Sold 1,250,000 shares of common stock to accredited investors for aggregate proceeds of ~$2.0M.
Reverse stock split amendment approved; Board authorized to determine ratio and timing at discretion.
Marcum LLP resigned as independent auditor effective April 11, 2025; Audit Committee approved CBIZ CPAs P.C. as successor the same day.
Exclusive distribution of consumer health/dietary supplements from Nov 1, 2024 to Dec 31, 2030; auto-renews for 6 years if targets met.
Harvard Apparatus Regenerative Technology appoints StellarS Capital CEO Mao Zhang to board
Mao Zhang, Founder & CEO of multi-billion-dollar alternative asset manager StellarS Capital, appointed as independent Class I director effective Aug 26, 2024.
Harvard Apparatus raises $5.0M via private placement of 1.39M shares at $3.60/share
Sold 1,388,888 shares to Stellars Capital at $3.60/share for approx $5.0 million.
David Green, Ting Li, and Ronald Packard elected as Class II directors for three-year terms.
Aggregate purchase price of $1.5 million for 367,767 shares at $4.03 per share in a private placement.
Harvard Apparatus Regenerative Technology enters $500K bridge note with CEO Junli He at 8% interest
Bridge note for $500,000 from Chairman/CEO Junli He; 8% annual interest on 360-day basis.
Name changed from Biostage to Harvard Apparatus Regenerative Technology; new ticker HRGN on OTCQB effective July 20, 2023.
Biostage annual meeting: all four proposals pass, equity plan amended
Junli He and James Shmerling elected as Class I directors; He received 10,377,115 'for' votes, Shmerling 2,345,415 'for' with 8,041,390 withheld.
Biostage reduces CEO milestone stock options from 488,256 to 267,616 shares
Amendment corrects Milestone Grant for CEO Junli He from 488,256 to 267,616 shares.
Biostage appoints Ron Packard, CEO of Pansophic Learning, to Board of Directors
Ron Packard appointed as Class II director effective April 5, 2023; term until 2024 annual meeting.
Biostage raises ~$6M via private placement of 1M shares at $6.00; preferred stock converted
Gross proceeds ~$6M from sale of 1,000,967 shares at $6.00/share; $3.6M received by Apr 5, 2023.
Biostage appoints Jerry He as CEO, replacing David Green; sets compensation terms
Jerry He appointed Chairman and CEO effective March 1, 2023; David Green remains on board.
Biostage appoints Jerry He as Chairman and CEO; David Green remains on Board
Jerry He appointed Chairman and CEO effective March 1, 2023, replacing David Green.
Biostage CEO David Green reduces cash salary to $35,568; receives $264K stock option
CEO David Green reduced annual base salary from $300,000 to $35,568 (minimum required by law).
Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options
Interim tag removed; David Green named permanent CEO effective January 11, 2023.
Biostage selects IQVIA as CRO for FDA-approved esophageal implant trial
IQVIA, a global CRO with GI and cell-therapy trial experience, to manage Biostage's first clinical trial.
Biostage Announces Publication Showing Rapid Esophageal Regeneration in Pigs
Publication in Journal of Immunology and Regenerative Medicine describes regeneration after Biostage Esophageal Implant in nine pigs with full circumferential replacement.
Biostage reports Q3 net loss of $1.1M ($0.10/share); cash runway into Q2 2023
Net loss $1.1M for Q3 2022 vs $0.8M in Q3 2021; EPS -$0.10 vs -$0.08.
Dismissed Wei, Wei & Co. as independent auditor on Oct 10, 2022.
Biostage adopts annual say-on-pay votes after stockholder advisory vote
Advisory vote: 7,539,731 shares favored one year, 28,038 three years, 110,760 abstained.
Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant
Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.
Biostage reports Q2 2022 net loss of $1.3M; raises $5.1M in private placement
Net loss of $1.3M ($0.12 per share) vs $0.4M loss in Q2 2021; increase due to higher legal costs and prior-year PPP loan forgiveness.
Biostage shareholders approve reverse stock split ratio of 1-for-1.25 to 1-for-5
Proposal to amend charter to effect reverse stock split approved with 7,072,052 votes for, 196,116 against, 742 abstained.
Biostage shareholders elect Chen and Sanchez as Class III directors
Jason Jing Chen elected with 7,668,383 votes for, 11,776 withheld.
Biostage issues $4M Series E Convertible Preferred to Harvard Bioscience to satisfy indemnification
Issued 4,000 shares of Series E Preferred at $1,000/share to HBIO on June 10, 2022, to settle $4M indemnification obligations.
Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement
Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.
Biostage raises $5.1M in private placement to advance esophageal implant clinical trial
Raised ~$5.1M from new and existing investors via 854,771 shares and warrants for 427,390 shares at $5.92/unit.
Biostage settles wrongful death litigation; to issue $4M convertible preferred to HBIO
Biostage settles 2017 wrongful death suit; total costs estimated at ~$6M, $5.7M unpaid.
Biostage FY2021 net loss widens to $8.0M on $3.3M litigation charge and higher legal costs
Q4 2021 net loss of $5.9M ($0.55/share) vs $1.0M loss in Q4 2020; FY2021 loss $8.0M ($0.79/share).
Biostage posted video of January 27 webinars with founder/interim CEO David Green.
Biostage wins court order requiring insurer to pay legal defense; to host investor webinar Jan 27
Court ordered Medmarc to continue paying Biostage's legal defense in a wrongful death suit over a tracheal implant, finding Medmarc breached its duty and awarding attorneys' fees.
Biostage highlights first-in-human esophageal success, FDA-approved IND, founder CEO return
First-in-human esophageal implant at Mayo Clinic; paper published Aug 2021 concludes 'considerable clinical use'.
Biostage appoints David Green as interim CEO; he invests $250,000 in private placement
David Green appointed Interim CEO and Chairman; Jason Chen becomes Vice Chairman.
Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022
Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.
On Sept 15, 2021, a product liability insurer denied coverage for the 2017 wrongful death suit and will stop defending after Sept 30, 2021.
Biostage raises $2.6M in private placements, appoints Jerry He to board
Raised $2.0M in Sept 2021 from DST Capital and An Zhang in private placement of 1M shares and warrants for 500K shares at $2.00 per unit.
Biostage Q2 net loss narrows to $0.4M; cash $0.5M, funding into Q3 2021
Net loss of $0.4M ($0.04 per share) vs $1.2M loss in Q2 2020.
Biostage replaces auditor RSM with Wei, Wei & Co. effective July 6, 2021
RSM US LLP notified Biostage on May 25, 2021 that client-auditor relationship ceased.
On August 26, 2024, Mao Zhang, the Founder and Chief Executive Officer of Stellars Capital, joined the Board of Directors (the “Board”) of the Company as a Class I director.
On April 5, 2023, Ron Packard, the Chief Executive officer of Pansophic Learning, joined the Board of Directors (the “Board”) of the Company as a Class II director.
the Company’s existing director, Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.
the Company’s existing director, Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.
in replacement of David Green in such roles.
Junli (Jerry) He, was appointed Chairman and Chief Executive Officer of the Company, in replacement of David Green in such roles.
Effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interim designation from his Chief Executive Officer title effective immediately
Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.
Mr. Green also joined the Board as a Class II director and was appointed Chairman of the Board.
Effective as of November 26, 2021, the Company appointed Mr. Green as Interim Chief Executive Officer.
the Company’s existing Chairman, Jason Chen, was appointed Vice Chairman of the Board.
On September 1, 2021, Junli He, the Executive Vice Chairman of Bright Scholar Holdings, joined the Board of Directors (the “Board”) of the Company as a Class I director.
Max materiality 0.75 · Median 0.60 · Most common event other_material